marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-06-2024
Aligos Therapeutics Financial Statements 2011-2024 | ALGS
Annual Financial Statements Aligos Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
55.9 M | 55.1 M | 473 M | 1.04 B | - | - | - | - | - | - | - | - | - |
Shares |
64.3 M | 42.7 M | 39.9 M | 36.9 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
0.87 | 1.29 | 11.9 | 27.6 | - | - | - | - | - | - | - | - | - |
Net Income |
-87.7 M | -96 M | -128 M | -109 M | -52.3 M | -13.9 M | - | - | - | - | - | - | - |
Revenue |
6.19 M | - | - | -10.5 M | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | -10.5 M | - | - | - | - | - | - | - | - | - |
Operating Income |
-88.1 M | -97.6 M | -128 M | -97.8 M | -54 M | - | - | - | - | - | - | - | - |
Interest Expense |
4.3 M | 1.5 M | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-86.6 M | -95.3 M | -125 M | -94.5 M | -51.7 M | -12.4 M | - | - | - | - | - | - | - |
Operating Expenses |
104 M | 111 M | 133 M | 97.8 M | 54 M | 13.7 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
30.6 M | 26.4 M | 28.5 M | 17.9 M | 10 M | 3.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Aligos Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
156 M | 156 M | 75.1 M | 43.5 M | 43.2 M | 42.9 M | 42.9 M | 42.8 M | 42.7 M | 42.5 M | 42.7 M | 42.4 M | 37.6 M | 37.4 M | 38.1 M | 3.03 M | 2.81 M | 2.65 M | 3.93 M | 2.08 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
5.06 M | -34.9 M | - | -18 M | -18.8 M | -23 M | - | -18.6 M | -19.9 M | -35.6 M | - | -33.1 M | -29.8 M | -27.7 M | - | -33.3 M | -20.8 M | -20 M | - | -14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
1.06 M | 694 K | - | 1.08 M | 4.29 M | 140 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-26.4 M | -22 M | - | -19.1 M | -19.1 M | -23.9 M | - | -18.9 M | -20.4 M | -35.6 M | - | -33.1 M | -29.6 M | -27.7 M | - | -21.6 M | -21.3 M | -20.7 M | - | -14.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
300 K | 600 K | - | - | 1 M | 700 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-26.1 M | -21.8 M | - | -18.8 M | -18.7 M | -23.5 M | - | -18.4 M | -19.8 M | -34.9 M | - | -32.3 M | -28.8 M | -27 M | - | -20.8 M | -20.6 M | -20.4 M | - | -14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
27.5 M | 23 M | - | 22.3 M | 26 M | 26.6 M | - | 23.1 M | 24.1 M | 38.1 M | - | 34.6 M | 31.1 M | 28.6 M | - | 21.6 M | 21.3 M | 20.7 M | - | 14.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
6.38 M | 6.67 M | - | 6.44 M | 9.25 M | 8.51 M | - | 5.26 M | 7.58 M | 6.45 M | - | 6.47 M | 6.56 M | 5.78 M | - | 4.22 M | 4.1 M | 3.42 M | - | 2.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency